Humira vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Humira | US Otezla | |
|---|---|---|
| Generic name | adalimumab | apremilast |
| Drug class | TNF Inhibitor (Biologic) | PDE4 Inhibitor |
| Treats | Rheumatoid arthritis, psoriasis, Crohn's disease | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Amgen |
| Year approved | 2002 | 2014 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $500M | $110M |
| Common side effects | Serious infections, Increased cancer risk, Allergic reactions, Injection site reactions | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Humira or Otezla better?
Neither is universally "better." Humira (adalimumab) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Humira and Otezla?
Humira is a TNF Inhibitor (Biologic) made by AbbVie, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Humira has the larger estimated TV advertising budget of the two.